SAB Biotherapeutics (SABS) Accumulated Depreciation (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Accumulated Depreciation came in at $18.1 million in Q1 2026, up 18.27% YoY from $15.3 million in Q1 2025, and up 3.47% on a QoQ basis from $17.5 million in Q4 2025.
SAB Biotherapeutics (SABS) Accumulated Depreciation (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Accumulated Depreciation data on file, last reported at $18.1 million in Q1 2026.
- Quarterly Accumulated Depreciation rose 18.27% year-over-year to $18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (up 18.27% YoY) and the FY2025 annual result came in at $17.5 million, up 20.19% from the prior year.
- Accumulated Depreciation climbed to $18.1 million in Q1 2026, from $17.5 million in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $18.1 million in Q1 2026 to a low of $3.8 million in Q1 2022.
- A 5-year average of $11.7 million and a median of $12.9 million in 2024 frame the typical range for Accumulated Depreciation.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation soared 94.98% — and 2026, when it grew 18.27%.
- Tracing SABS's Accumulated Depreciation over 5 years: stood at $6.3 million in 2022, then surged by 57.87% to $9.9 million in 2023, then jumped by 47.04% to $14.6 million in 2024, then gained by 20.19% to $17.5 million in 2025, then advanced by 3.47% to $18.1 million in 2026.
- The last three Accumulated Depreciation figures came in at $18.1 million (Q1 2026), $17.5 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.75 Mn |
| Mar 31, 2026 | 18.12 Mn |
| Dec 31, 2025 | 17.52 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | 16.08 Mn |
| Mar 31, 2025 | 15.32 Mn |
| Dec 31, 2024 | 14.57 Mn |
| Sep 30, 2024 | 13.85 Mn |
| Jun 30, 2024 | 12.91 Mn |
| Mar 31, 2024 | 11.87 Mn |
| Dec 31, 2023 | 9.91 Mn |
| Sep 30, 2023 | 8.99 Mn |
| Dec 31, 2022 | 6.28 Mn |
| Sep 30, 2022 | 5.38 Mn |
| Jun 30, 2022 | 4.51 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 3.22 Mn |
| Dec 31, 2020 | 1.77 Mn |